LVAD – Medxy AI

Evaluating the Impact of the OPTN Status Escalation Policy for Adult Heart Transplant Candidates on Durable LVAD Support

By MedXY 06/24/2026

The OPTN's new status escalation policy for stable adult heart transplant candidates with durable LVADs may benefit only a small fraction of patients, as most experience complications or transplant within six years.

Cardiology Diabetes & Endocrinology news

Insulin Resistance Blunts LVAD-Mediated Myocardial Recovery by Impairing the Pentose Phosphate Pathway

By MedXY 03/02/2026

Obesity-induced insulin resistance hinders heart failure recovery post-LVAD by disrupting the pentose phosphate pathway. A new study in Circulation suggests insulin sensitizers could restore cardiac repair mechanisms in obese patients.

Cardiology Critical Care news Transplantation

The LVAD Paradox in Heart Transplantation: Higher Risk of Primary Graft Dysfunction, Yet Improved Survival Outcomesdszcx

By MedXY 12/29/2025

A large-scale multicenter study reveals that while pre-transplant durable LVAD support increases the incidence of severe primary graft dysfunction (PGD), these patients paradoxically demonstrate significantly better survival rates compared to non-LVAD patients who develop PGD.

Cardiology news

Summary of ARIES-HM3 Clinical Trial Publications on Aspirin Use and Hemocompatibility in LVAD Patients

By MedXY 11/28/2025

Comprehensive review of ARIES-HM3 trial findings showing aspirin avoidance with vitamin K antagonists in HeartMate 3 LVAD patients reduces bleeding without increasing thrombotic events, supported by analyses across subgroups and anticoagulation quality.